- GlobeNewswire•15 days agoAddex's Clinical Programs and Discovery Platform Highlighted in Review of Allosteric Modulators for the Treatment of Neurodegenerative Diseases
Geneva, Switzerland, 6 February 2017 - Addex Therapeutics (SIX: ADXN) announced today the publication of a review summarizing the current status of allosteric modulators (AMs) as potential novel treatments ...
- GlobeNewswire•21 days agoAddex Awarded $835,000 Grant from Michael J. Fox Foundation to Advance TrkB PAMs for the Treatment of Parkinson's Disease
Geneva, Switzerland, 31 January 2017 - Addex Therapeutics (SIX: ADXN) announced today that The Michael J. Fox Foundation for Parkinson`s Research (MJFF) has awarded the Company an $835,000 grant towards ...
- GlobeNewswire•last monthAddex ADX71441 Demonstrates Statistically Significant Efficacy in a Highly Translational Preclinical Model of Chronic Osteoarthritis Pain
Geneva, Switzerland, 9 January 2017 - Addex Therapeutics (SIX: ADXN), announced today that ADX71441, a positive allosteric modulator (PAM) of the gamma-aminobutyric acid subtype B (GABAB) receptor demonstrated ...
ADXN.SW : Summary for ADDEX N - Yahoo Finance
Addex Therapeutics Ltd (ADXN.SW)
Swiss - Swiss Delayed Price. Currency in CHF
Add to watchlist
|Day's Range||2.20 - 2.25|
|52 Week Range||1.70 - 3.10|
|PE Ratio (TTM)||-9.49|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|